Literature DB >> 16306444

Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury.

Ramesh Natarajan1, Fadi N Salloum, Bernard J Fisher, Rakesh C Kukreja, Alpha A Fowler.   

Abstract

Hypoxia inducible factor-1 (HIF-1) regulates changes in transcription of key genes such as inducible NO synthase (iNOS) in hypoxic/ischemic environments. In normoxia, HIF-1 activation is controlled by HIF-1alpha-prolyl 4-hydroxylases, which target HIF-1alpha for ubiquitination and proteasomal degradation. We hypothesized that normoxic HIF-1 preservation could attenuate cardiac ischemia/reperfusion injury via a preconditioning effect. HIF-1 preservation was achieved by using small interfering RNA (siRNA) to silence murine HIF-1alpha-prolyl-4 hydroxylase-2 (PHD2). PHD2 siRNA reduced PHD2 mRNA expression 89+/-1.5% (P<0.001) in a time- and concentration-dependent manner in normoxic murine microvascular endothelial cells (EC). PHD2 silencing in normoxic EC stabilized HIF-1alpha protein levels while significantly increasing HIF-1 transcriptional activity and iNOS mRNA expression. Wild-type mice infused with PHD2 siRNA (1.5 microg/g body weight) showed a 61+/-2.4% (P<0.05) reduction in cardiac PHD2 mRNA within 24 hours. In addition HIF-1alpha protein levels and HIF-1-dependent iNOS mRNA levels were increased. PHD2 siRNA-transfected hearts from wild-type mice (n=6) subjected to 30 minutes ischemia followed by 60 minutes reperfusion exhibited reduced infarct size when compared with saline-treated controls (9.7+/-1.9% versus 31.6+/-1.8%, respectively, P<0.0001, n=6) and to control mice transfected with a nontargeting siRNA control (28.4+/-3.0%, P<0.0001, n=6). Hearts from iNOS knockout mice receiving PHD2 siRNA by identical injection protocol (n=6) exhibited infarct size indistinguishable from saline controls (28.7+/-1.3%). These results show that in vitro and in vivo, PHD2 silencing using a siRNA strategy produces transcriptionally active HIF-1. Normoxic activation of HIF-1 in hearts following in vivo PHD2 siRNA administration attenuates reperfusion injury via an iNOS-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306444     DOI: 10.1161/01.RES.0000197816.63513.27

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  64 in total

1.  Toll-like receptor 7/8 agonist resiquimod induces late preconditioning in neonatal cardiac myocytes.

Authors:  Yong-yi Wang; Sha Liu; Feng Lian; Wen-gang Yang; Song Xue
Journal:  Acta Pharmacol Sin       Date:  2011-04-25       Impact factor: 6.150

Review 2.  Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.

Authors:  Vaithinathan Selvaraju; Narasimham L Parinandi; Ram Sudheer Adluri; Joshua W Goldman; Naveed Hussain; Juan A Sanchez; Nilanjana Maulik
Journal:  Antioxid Redox Signal       Date:  2013-10-31       Impact factor: 8.401

3.  P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway.

Authors:  Jijun Zhao; Hongyue Wang; Chao Dai; Hongyang Wang; Hui Zhang; Yuefang Huang; Shuang Wang; Felicia Gaskin; Niansheng Yang; Shu Man Fu
Journal:  Arthritis Rheum       Date:  2013-12

4.  Activation of hypoxia-inducible factor-1 ameliorates postischemic renal injury via inducible nitric oxide synthase.

Authors:  Xiao-Li Zhang; Zhen-Wen Yan; Wei-Wen Sheng; Jing Xiao; Zhen-Xing Zhang; Zhi-Bin Ye
Journal:  Mol Cell Biochem       Date:  2011-07-14       Impact factor: 3.396

Review 5.  Antisense makes sense in engineered regenerative medicine.

Authors:  Yongchang Yao; Chunming Wang; Rohan R Varshney; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

Review 6.  Reductive stress in striated muscle cells.

Authors:  Ilaria Bellezza; Francesca Riuzzi; Sara Chiappalupi; Cataldo Arcuri; Ileana Giambanco; Guglielmo Sorci; Rosario Donato
Journal:  Cell Mol Life Sci       Date:  2020-02-18       Impact factor: 9.261

Review 7.  MicroRNAs: new players in cardiac injury and protection.

Authors:  Rakesh C Kukreja; Chang Yin; Fadi N Salloum
Journal:  Mol Pharmacol       Date:  2011-07-07       Impact factor: 4.436

8.  Dexmedetomidine protects against lung ischemia-reperfusion injury by the PI3K/Akt/HIF-1α signaling pathway.

Authors:  Wei Zhang; Jia-Qiang Zhang; Fan-Min Meng; Fu-Shan Xue
Journal:  J Anesth       Date:  2016-07-13       Impact factor: 2.078

Review 9.  Redox signaling in cardiovascular health and disease.

Authors:  Nageswara R Madamanchi; Marschall S Runge
Journal:  Free Radic Biol Med       Date:  2013-04-11       Impact factor: 7.376

10.  Short hairpin RNA interference therapy for ischemic heart disease.

Authors:  Mei Huang; Denise A Chan; Fangjun Jia; Xiaoyan Xie; Zongjin Li; Grant Hoyt; Robert C Robbins; Xiaoyuan Chen; Amato J Giaccia; Joseph C Wu
Journal:  Circulation       Date:  2008-09-30       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.